Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27559156 | 0.89 | SLC6A2 (0.39) | CYP3A4TSHRSLC6A2HTR2ASLC6A4 | |
| SCHEMBL19118090 | 0.85 | CYP3A4 (0.63) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL11786125 | 0.81 | CYP2A6 (0.36) | CYP3A4TSHRSLC6A2HTR2ASLC6A4 | |
| SCHEMBL9718076 | 0.80 | IDO1 (0.39) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL11785888 | 0.79 | SLC6A2 (0.52) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL19041517 | 0.79 | ESR1 (0.36) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL4842726 | 0.77 | PYCR1 (0.39) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL13893483 | 0.76 | CYP3A4 (0.52) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL1647777 | 0.76 | CYP3A4 (0.61) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL30480110 | 0.74 | ATM (0.37) | CYP3A4CYP1A2SLC6A2GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1155418-B1 | MEDICAL TOOLS AND DEVICES WITH IMPROVED ULTRASOUND VISIBILITY | GE HEALTHCARE LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-6551806-B1 | Reacting a diisocyanate or diisothiocyanate and a diamine in solvent with the enzyme to form the enzyme immobilized in a polyurea or polythiourea; use in acylation or enantioselective acylation of alcohols | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-22 | — | — | US | disclosed |
| EP-1102839-B1 | ENZYME-CONTAINING POLYMERS | BASF AG (DE) | 2002-10-02 | — | — | EP | disclosed |
| EP-1102839-A2 | ENZYME-CONTAINING POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000005354-A2 | ENZYME-CONTAINING POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | CYP3A4 1815/4885TSHR 4182/4885CYP1A2 2780/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | CYP3A4 1760/4885TSHR 588/4885CYP1A2 601/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CYP3A4 2166/4885TSHR 4185/4885CYP1A2 2966/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CYP3A4 2166/4885TSHR 4185/4885CYP1A2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.